United Therapeutics CEO Martine Rothblatt Buys Shares
Martine Rothblatt, CEO of United Therapeutics, purchased 9,500 shares in a recent transaction.
Key Points
- Martine Rothblatt, CEO of United Therapeutics, purchased 9,500 shares valued at approximately $1.29 million on June 26, 2026.
- United Therapeutics traded at $548.11 on Tuesday, with a market cap of about $23.03 billion and a P/E ratio of 20.05.
- Analysts maintain a positive outlook, with RBC Capital and Wells Fargo giving 'buy' ratings and targets up to $738.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, recently purchased 9,500 shares of the company. This transaction, valued at about $1.29 million, occurred on June 26, 2026. The shares were acquired at an average price of $135.42 each, as disclosed in a recent filing.
Insider Buying and Selling at United Therapeutics Corporation
Martine Rothblatt's purchase on June 26, 2026, added 9,500 shares to her holdings, acquired at $135.42 per share. This transaction was not part of a pre-planned trading program. On the same date, Rothblatt also executed planned sales at various prices, reflecting her active management of her position in the company.
Other Institutional Activity in United Therapeutics
Several institutional investors have adjusted their positions in United Therapeutics. BlackRock, Inc. increased its holdings by 228,883 shares, totaling 5,399,649 shares valued at approximately $3.2 billion. Avoro Capital Advisors LLC added 23,940 shares, ending with 2,630,000 shares worth about $1.56 billion. Meanwhile, Wellington Management Group LLP reduced its stake by 177,245 shares, holding 2,264,247 shares valued at roughly $1.34 billion. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both established new positions, with 2,003,742 and 1,957,539 shares, respectively.
United Therapeutics Corporation Stock Up 4.5%
Shares of NasdaqGS:UTHR traded near $548.11 on Tuesday. United Therapeutics has a market cap of approximately $23.03 billion and a P/E ratio of 20.05. The stock's 52-week range is between $272.12 and $609.35, with a 50-day moving average of $562.17 and a 200-day moving average of $501.21. The company maintains a strong liquidity position with a current ratio of 4.79 and a quick ratio of 4.12.
$UTHR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have set new price targets for United Therapeutics. On May 7, 2026, RBC Capital maintained its 'buy' rating with a target price of $701, while Wells Fargo upgraded the stock to a 'buy' with a target of $738. The consensus among 13 analysts is a 'buy' recommendation, with a mean target price of $665.23.
About United Therapeutics
United Therapeutics Corporation is a healthcare company focused on developing and commercializing products to meet the needs of patients with chronic and life-threatening diseases. Based in Silver Spring, Maryland, the company offers various treatments for pulmonary arterial hypertension and other conditions. Led by CEO Dr. Martine A. Rothblatt, the company employs around 1,400 people.
Bottom Line
Martine Rothblatt's recent purchase of United Therapeutics shares reflects her ongoing commitment to the company. Investors often watch insider transactions for insights into management's confidence in the company's future. United Therapeutics continues to attract institutional interest, with analysts maintaining a positive outlook on its stock. As always, these insights are based on past filings and may not represent the current position of any investor.
Get United Therapeutics Corporation alerts
New 13F filings, insider trades, and analyst moves on $UTHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.